Considering the continuous growth and evolution of the Peptide therapeutic market, the strategy of the PolyPeptide Group is to anticipate the market needs and to extend its available capacities. Our strategy is to invest in new manufacturing capacities and constantly improve the productivity of our assets through the deployment of innovative, cost-efficient and sustainable technology solutions.
In recent years, we have made considerable investment in small, medium and large scale capacities to satisfy the needs of our customers from early stage to commercial productions.
In regard to the technology, we have implemented our latest innovative and “state of the art” features at all of our sites that includes, but is not limited to, mechanical design, online monitoring and full automation.
An illustration of this approach is our SPPS 600L reactor recently installed in Braine-L’Alleud, Belgium. Our optimized design provides multiple benefits including:
The necessary cookies help to make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
Marketing cookies are used to track visitors through websites. The goal is to display ads that are relevant and interesting to the individual user and therefore more valuable to third-party publishers and advertisers.
Statistical cookies help website owners, through the anonymous collection and communication of information, to understand how visitors interact with websites.
Preferences cookies allow a website to retain information that changes the way the site behaves or displays, such as your preferred language or the region in which you are located.
COVID-19 Outbreak Information –